The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been
highly effective. However, there remain few practical antibodies against viruses that are …

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

Many methods have been developed to measure the neutralizing capacity of antibodies to
SARS-CoV-2. However, these methods are low throughput and can be difficult to quickly …

Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

Neutralizing antibodies are a major correlate of protection for many viruses including the
novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak …

The COVID-19 pandemic spurred the rapid development of a range of therapeutic antibody
treatments. As part of the US government's COVID-19 therapeutic response, a research …